UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/705,227	11/12/2003	John D. Pruitt	029318-0985	3550	
	7590 10/15/200 very, Inc. c/o Foley & I	EXAMINER			
3000 K Street, I	•	FUBARA, BLESSING M			
Suite 500 Washington, DC 20007-5109			ART UNIT	PAPER NUMBER	
_			1618		
			MAIL DATE	DELIVERY MODE	
			10/15/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/705,227	PRUITT ET AL.		
Examiner	Art Unit		
BLESSING M. FUBARA	I I		

	BLESSING M. FUBARA	1618	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ess
THE REPLY FILED 29 September 2008 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
1.  The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appetor Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Anno event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	iter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE ).	date of the final rejectio	n. .ED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of the hortened statutory period for reply original for the hortened statutory period for reply original for the hortened statutory period for reply original for the hortened statutory and the corresponding amount of the hortened statutory and the corresponding amount of the hortened statutory and the corresponding amount of the	of the fee. The appropria nally set in the final Office	ite extension fee e action; or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS</li> </ol>	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be	out prior to the date of filing a brief	will not be entered be	naueo.
(a) ☐ They raise new issues that would require further cor (b) ☐ They raise the issue of new matter (see NOTE below (c) ☐ They are not deemed to place the application in better	nsideration and/or search (see NOT w);	E below);	
appeal; and/or	11 3	3 1 7 3	
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	cted claims.	
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Cor	mpliant Amendment (F	PTOL-324).
5. Applicant's reply has overcome the following rejection(s):	·		
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>	owable if submitted in a separate, t	imely filed amendmen	t canceling the
7.  For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows:		be entered and an ex	planation of
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected: <u>1-17,19-26,28-30 and 37-57</u> . Claim(s) withdrawn from consideration: <u>27 and 31-36</u> .			
<u>AFFIDAVIT OR OTHER EVIDENCE</u> 8.	hefore or on the date of filing a No	tice of Anneal will not	he entered
because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea and was not earlier presented. Se	ıl and/or appellant fails ee 37 CFR 41.33(d)(1)	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attache	ed.
The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowand	ce because:
<ul><li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li><li>13. ☐ Other:</li></ul>	PTO/SB/08) Paper No(s)		
/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618			

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's statement that the claimed invention does not require the presence of erythritol that is mandatory in Murakami is not persuasive because the comprising language of the claims is open; further, applicant's argument that the friability of the dosage form cannot be inherent because the claimed dosage form is distinguished from the prior art composition is not persuasive because as discussed above, the comprising language of the claims do not exclude the presence of erythritol and as such the composition of the prior art is not different and it flows that the friability of the composition, which is a property of the composition would be inherent. The rejection under 35 USC 112, 2nd is withdrawn since aerosol formulations can be of dry powdered form.

/BF/